SCHEMBL17234496

SCHEMBL17234496

NCCS/N=C(\N)NCCC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ECE1 P42892 2/20 0.35
▸ ITGB3 P05106 5/20 0.34
▸ ITGA2B P08514 5/20 0.34
▸ LMNA P02545 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ THRB P10828 2/20 0.33
▸ BLM P54132 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ GABRR3 A8MPY1 1/20 0.33
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ GABBR2 O75899 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRR1 P24046 1/20 0.33
▸ GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23566644 1.00 ECE1 (0.35) ECE1ITGB3ITGA2BLMNAKMT2A
SCHEMBL24241848 0.86 ECE1 (0.38) ECE1ITGB3ITGA2BLMNAKMT2A
SCHEMBL23566522 0.82 ECE1 (0.37) ECE1ITGB3ITGA2BCYP1A2CYP2D6
SCHEMBL17234501 0.82 ECE1 (0.37) ECE1ITGB3ITGA2BCYP1A2CYP2D6
SCHEMBL23586969 0.81 ECE1 (0.35) ECE1ITGB3ITGA2BALDH1A1CA1
SCHEMBL17234493 0.81 CA1 (0.33) ECE1ALDH1A1CA1CA2
SCHEMBL23566571 0.81 CA1 (0.33) ECE1ALDH1A1CA1CA2
SCHEMBL17234499 0.80 BHMT (0.47) LMNAKMT2ACYP1A2BLMTSHR
SCHEMBL18528324 0.80 BHMT (0.47) LMNAKMT2ACYP1A2BLMTSHR
SCHEMBL17224704 0.76 GRM8 (0.39) ECE1ITGB3ITGA2BKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023004308-A1 COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER INSPIRNA, INC. (US) 2023-01-26 — — WO disclosed
EP-3950673-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF Inspirna, Inc. (US) 2022-02-09 — — EP disclosed
US-10717704-B2 Inhibitors of creatine transport and uses thereof RGENIX, INC. (US) 2020-07-21 — — US disclosed
US-20190315680-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF INSPIRNA, INC. 2019-10-17 — — US disclosed
US-10308597-B2 Inhibitors of creatine transport and uses thereof RGENIX, INC. (US) 2019-06-04 — — US disclosed
US-20170050924-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF INSPIRNA, INC. 2017-02-23 — — US disclosed
US-20170050924-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF INSPIRNA, INC. 2017-02-23 — — US disclosed
WO-2016176636-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF RGENIX, INC. (US) 2016-11-03 — — WO disclosed
WO-2015168465-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF RGENIX, INC. (US) 2015-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717704-B2 Inhibitors of creatine transport and uses thereof CKMT1A; CKMT1B, SLC25A1, SLC2A1 ECE1 2290/4885ITGB3 4144/4885ITGA2B 4286/4885
US-10308597-B2 Inhibitors of creatine transport and uses thereof CKMT1A; CKMT1B, SLC25A1, SLC2A1 ECE1 2290/4885ITGB3 4144/4885ITGA2B 4286/4885
US-20170050924-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF CKMT1A; CKMT1B, SLC25A1, SLC2A1 ECE1 2290/4885ITGB3 4144/4885ITGA2B 4286/4885
US-20190315680-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF CKMT1A; CKMT1B, SLC25A1, SLC2A1 ECE1 2290/4885ITGB3 4144/4885ITGA2B 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback